{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:32Z","timestamp":1791475532036,"version":"4.3.4"},"reference-count":27,"publisher":"The Endocrine Society","issue":"7","license":[{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UCSF-CTSI Grant Number UL1 TR000004"],"award-info":[{"award-number":["UCSF-CTSI Grant Number UL1 TR000004"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"DOI":"10.1210\/jc.2018-02335","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T14:06:40Z","timestamp":1551276400000},"page":"2735-2747","source":"Crossref","is-referenced-by-count":75,"title":["Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study"],"prefix":"10.1210","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-3171","authenticated-orcid":false,"given":"Christine E","family":"Hofmann","sequence":"first","affiliation":[{"name":"University Children\u2019s Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[{"name":"University of California San Francisco Benioff Children\u2019s Hospital Oakland, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Vockley","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania"},{"name":"University of Pittsburgh, Graduate School of Public Health, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Adolescent Medicine, Johannes Kepler University, Linz, Austria"},{"name":"Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Nakayama","sequence":"additional","affiliation":[{"name":"Fukuoka Higashi Medical Center, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bishop","sequence":"additional","affiliation":[{"name":"Sheffield Children\u2019s Hospital, Sheffield, United Kingdom"},{"name":"University of Sheffield, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel \u00c1","family":"Martos-Moreno","sequence":"additional","affiliation":[{"name":"Hospital Infantil Universitario Ni\u00f1o Jes\u00fas, IIS La Princesa, Madrid, Spain"},{"name":"Universidad Aut\u00f3noma de Madrid, Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de la Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Moseley","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc., Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji P","family":"Fujita","sequence":"additional","affiliation":[{"name":"Alexion Pharmaceuticals, Inc., Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Liese","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Rockman-Greenberg","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada"},{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ENB-010-10 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"2019052212000015600_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/B978-0-12-804182-6.00028-9","article-title":"Hypophosphatasia and how alkaline phosphatase promotes mineralization","volume-title":"Genetics of Bone Biology and Skeletal Disease","author":"Whyte","year":"2018","edition":"2nd ed"},{"key":"2019052212000015600_bib2","first-page":"380","article-title":"Hypophosphatasia","volume":"10","author":"Rockman-Greenberg","year":"2013","journal-title":"Pediatr Endocrinol Rev"},{"issue":"2","key":"2019052212000015600_bib3","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1172\/JCI112031","article-title":"Markedly increased circulating pyridoxal-5\u2032-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism","volume":"76","author":"Whyte","year":"1985","journal-title":"J Clin Invest"},{"issue":"5065","key":"2019052212000015600_bib4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"issue":"6","key":"2019052212000015600_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.bone.2007.01.020","article-title":"Pyridoxine-responsive seizures as the first symptom of infantile hypophosphatasia caused by two novel missense mutations (c.677T>C, p.M226T; c.1112C>T, p.T371I) of the tissue-nonspecific alkaline phosphatase gene","volume":"40","author":"Baumgartner-Sigl","year":"2007","journal-title":"Bone"},{"key":"2019052212000015600_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","article-title":"Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients","volume":"75","author":"Whyte","year":"2015","journal-title":"Bone"},{"issue":"2","key":"2019052212000015600_bib7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00975316","article-title":"Hypophosphatasia. Review of 24 cases","volume":"5","author":"Kozlowski","year":"1976","journal-title":"Pediatr Radiol"},{"issue":"5","key":"2019052212000015600_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/0002-9343(57)90124-9","article-title":"Hypophosphatasia","volume":"22","author":"Fraser","year":"1957","journal-title":"Am J Med"},{"issue":"2","key":"2019052212000015600_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00381-008-0708-3","article-title":"Neurosurgical aspects of childhood hypophosphatasia","volume":"25","author":"Collmann","year":"2009","journal-title":"Childs Nerv Syst"},{"issue":"5","key":"2019052212000015600_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/15513818809022304","article-title":"Pulmonary hypoplasia in neonatal hypophosphatasia","volume":"8","author":"Silver","year":"1988","journal-title":"Pediatr Pathol"},{"key":"2019052212000015600_bib11","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s10545-009-9012-y","article-title":"Perinatal hypophosphatasia presenting as neonatal epileptic encephalopathy with abnormal neurotransmitter metabolism secondary to reduced co-factor pyridoxal-5\u2032-phosphate availability","volume":"33","author":"Balasubramaniam","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"2019052212000015600_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/8904_2013_224","article-title":"Outcome of perinatal hypophosphatasia in manitoba mennonites: a retrospective cohort analysis","volume":"11","author":"Leung","year":"2013","journal-title":"JIMD Rep"},{"issue":"1","key":"2019052212000015600_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1297\/cpe.19.7","article-title":"Clinical characteristics of perinatal lethal hypophosphatasia: a report of 6 cases","volume":"19","author":"Nakamura-Utsunomiya","year":"2010","journal-title":"Clin Pediatr Endocrinol"},{"issue":"1","key":"2019052212000015600_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2019052212000015600_bib15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia\u2014aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2019052212000015600_bib16","unstructured":"European Medicines Agency. Strensiq (asfotase alfa) [EMEA summary of product characteristics; updated 29 January 2016]. Available at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003794\/human_med_001901.jsp&mid=WC0b01ac058001d124. Accessed 28 August 2018."},{"issue":"10","key":"2019052212000015600_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019052212000015600_bib18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2019052212000015600_bib19","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a novel scoring system for changes in skeletal manifestations of hypophosphatasia in newborns, infants, and children: the Radiographic Global Impression of Change scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2019052212000015600_bib20","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/tropej\/46.3.132","article-title":"Radiographic scoring method for the assessment of the severity of nutritional rickets","volume":"46","author":"Thacher","year":"2000","journal-title":"J Trop Pediatr"},{"issue":"246","key":"2019052212000015600_bib21","first-page":"1","article-title":"2000 CDC Growth Charts for the United States: methods and development","volume":"11","author":"Kuczmarski","year":"2002","journal-title":"Vital Health Stat 11"},{"key":"2019052212000015600_bib22","author":"World Health Organization"},{"issue":"1","key":"2019052212000015600_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/cen.13343","article-title":"Safety and efficacy of treatment with asfotase alfa in patients with hypophosphatasia: results from a Japanese clinical trial","volume":"87","author":"Kitaoka","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1\u20132","key":"2019052212000015600_bib24","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","article-title":"Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa","volume":"122","author":"Kishnani","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"9","key":"2019052212000015600_bib25","doi-asserted-by":"crossref","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"issue":"8","key":"2019052212000015600_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nbt.1484","article-title":"Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment","volume":"26","author":"Wang","year":"2008","journal-title":"Nat Biotechnol"},{"key":"2019052212000015600_bib27","author":"Martos-Moreno"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/7\/2735\/28695410\/jc.2018-02335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T01:52:26Z","timestamp":1574128346000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/7\/2735\/5364747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,2,27]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2018-02335","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,2,27]]}}}